Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant

The liver is the world's sixth most common primary tumor site, responsible for approximately 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, accounting for approximately 75% of all primary liver tumors. A major ther...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-06, Vol.15 (12), p.3165
Main Authors: Manzi, Joao, Hoff, Camilla O, Ferreira, Raphaella, Glehn-Ponsirenas, Renata, Selvaggi, Gennaro, Tekin, Akin, O'Brien, Christopher B, Feun, Lynn, Vianna, Rodrigo, Abreu, Phillipe
Format: Article
Language:English
Subjects:
Biopsy
Cancer
Cancer therapies
Decision making
Deoxyribonucleic acid
DNA
Extracellular vesicles
Genetic aspects
Graft rejection
Health aspects
Hepatitis B
Hepatocellular carcinoma
Hepatoma
Liver
Liver cancer
Liver diseases
Liver transplantation
Magnetic resonance imaging
MicroRNAs
Patients
Review
Surveillance
Transplantation
Transplants & implants
Tumor cells
Tumors
α-Fetoprotein
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The liver is the world's sixth most common primary tumor site, responsible for approximately 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, accounting for approximately 75% of all primary liver tumors. A major therapeutic tool for this disease is liver transplantation. Two of the most significant issues in treating HCC are tumor recurrence and graft rejection. Currently, the detection and monitoring of HCC recurrence and graft rejection mainly consist of imaging methods, tissue biopsies, and alpha-fetoprotein (AFP) follow-up. However, they have limited accuracy and precision. One of the many possible components of cfDNA is circulating tumor DNA (ctDNA), which is cfDNA derived from tumor cells. Another important component in transplantation is donor-derived cfDNA (dd-cfDNA), derived from donor tissue. All the components of cfDNA can be analyzed in blood samples as liquid biopsies. These can play a role in determining prognosis, tumor recurrence, and graft rejection, assisting in an overall manner in clinical decision-making in the treatment of HCC.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15123165